Gilmore Neil O'Neill - 03 Jun 2026 Form 4 Insider Report for Editas Medicine, Inc. (EDIT)

Reporting relationship: CEO, Director
Issuer ticker: EDIT
Reported as of: 03 Jun 2026
Net transaction value: -$41,543
SEC form: 4
Accepted by SEC: 05 Jun 2026, 16:33:02 UTC
Prior SEC filing: 16 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Gilmore O'Neill

Key filing fact

Gilmore Neil O'Neill filed Form 4 for Editas Medicine, Inc. (EDIT) on 05 Jun 2026.

Key facts

This page summarizes Gilmore Neil O'Neill's Form 4 filing for Editas Medicine, Inc. (EDIT).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 05 Jun 2026, 16:33.

Change

Previous filing in this sequence was filed on 16 Mar 2026.
Current net transaction value: -$41,543.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001742084 Primary reporting owner

O'Neill Gilmore Neil

Relationship: CEO, Director
Address: C/O EDITAS MEDICINE, INC., 11 HURLEY ST., CAMBRIDGE
Signature: /s/ Gilmore O'Neill
Signature date: 05 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

EDIT transaction

Common Stock

Sale

Transaction value: $41,543
Shares: -15,380
Change %: -5.8%
Price: $2.70
Shares after: 248,313
Date: 03 Jun 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on April 13, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on June 2, 2026. The sale does not represent a discretionary trade by the Reporting Person.

Footnote F2

This transaction was executed in multiple trades at prices ranging from $2.7010 to $2.7250. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.